ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2376

A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis

Alper M. van Sijl1, Michel W.P. Tsang-A-Sjoe1, Hennie G. Raterman1, Michael T. Nurmohamed2 and Alexandre E. Voskuyl3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2VU University Medical Center, Amsterdam, Netherlands, 3Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

For patients with rheumatoid arthritis (RA) who are refractory to tumor necrosis factor (TNF)-inhibitors, it is still not clear which determinants are associated with response when switching to rituximab (RTX). Prior studies have shown anti-CCP positivity and a lower number of previously-failed TNF inhibitors to be associated with good-to-moderate response. We developed a prediction model for response to rituximab with widely available clinical and laboratory parameters.

 

Methods:

RTX treated RA patients (n=115) were assessed prospectively for the following variables at baseline: demographic and disease characteristics, number of previous biologicals, co-morbidities, basic laboratory data, rheumatoid factor levels, anti-CCP levels and immunoglobulin levels (IgA, IgM and IgG). Clinical response was determined at 6 months after RTX initiation, using the European League Against Rheumatism (EULAR) response criteria for RA. Variables with p < 0.10 in univariate analyses were selected as candidate variables and entered into a forward and backward logistic regression analyses. A prediction model was constructed using backward logistic regression and an area under the curve (AUC) was calculated for the new prediction model.

Results: Mean disease activity score 28 (DAS28) was 5.34 at baseline and 4.44 at 6 months (p<0.001). A good-to-moderate response was achieved in 57 patients (49.6%). 101 patients (87.8%) used at least 1 biological prior to RTX treatment. RTX was re-administered in 70.9% of patients. The prediction model (see figure) consisted of age (in years), number of swollen joints, hydroxychloroquine use at baseline, steroid use at baseline and IgM level at baseline. The AUC (95% confidence interval) was 0.756 (0.663-0.850). When only using clinical variables (excluding IgM levels), the AUC was 0.714 (0.621-0.808).

Conclusion:

We developed a prediction model for response to rituximab with simple clinical and laboratory parameters. This model is easy to use and accurate in the prediction of response to treatment. Further validation of this model could make the implementation of this model cost-effective and patient friendly.

 

 

Figure. Area Under the Receiver Operating Characteristic (AUROC) of a predictive model of EULAR response at 6 months after RTX treatment (A) and the clinical determinants comprising the model (B)


Disclosure:

A. M. van Sijl,
None;

M. W. P. Tsang-A-Sjoe,
None;

H. G. Raterman,
None;

M. T. Nurmohamed,
None;

A. E. Voskuyl,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-and-effective-prediction-model-of-response-to-rituximab-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology